Solésence, Inc. (Nasdaq: SLSN), a leader in health care solutions across beauty and life science categories, announced on June 2, 2025, that it has amended its existing loan agreements to expand borrowing capacity. The amendments, made on May 27, 2025, increase the maximum borrowing capacity from $14.2 million to $23.0 million and extend the maturity date from October 1, 2025, to April 30, 2027. This enhanced financial flexibility will support Solésence's strategic objectives, including raw material procurement, packaging improvements, and product launches. CEO Jess Jankowski expressed gratitude for the support from banking partners and stakeholders, emphasizing the importance of this development in scaling operations and serving brand partners.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。